Identification of FDA compounds to inhibit RAGEs through docking, MD-simulation, MMPBSA and DFT analysis

Abstract

Abstract Receptor for advanced glycation end products (RAGEs) is a multifunctional cell surface protein present in vascular cells, monocytes/macrophages, B- and T-lymphocytes, retina Muller cells, kidney podocytes, mesangial cells, glial cells, neurons, and some cancer cells. The variety of cell types expresses RAGE, and AGEs ligand recognized by these receptor and produce signaling cascade mechanisms. The Accumulation of AGEs and recognisase by RAGEs play important roles in diabetes, chronic inflammatory disorders, neurological illnesses, and cancer, as well as T-lymphocyte proliferation. Therefore, block the RAGEs activity through FDA inhibitors are unmet need. In this studies, we targeted RAGE receptor and screening of FDA libraries through docking analysis. Docking studies identifed the best four FDA compounds Zytiga (ZINC000003797541), Paliperidone (ZINC000004214700), Targretin (ZINC000001539579), Irinotecan (ZINC000001612996) and Carboxymethyllysine (Control) were the medications examined; their respective ΔG values were -11.2, -11.2, -11.2, -11.1 and -5.0 kcal/mol respectively. Furthermore, 100 ns run was performed and found RMSD value of Paliperidone(1.2±0.3 nm) and Irinotecan (1.3± 0.2 nm) was quite stable. Next, docking and simulation experiment supported by MMPBSA analysis and found Paliperidone molecule was high negative energy (-13.49 kcal/mol). In silico investigation suggested that Paliperidone were involved in stable interactions which were maintained throughout the MD run with the RAGEs, virtually. The results advocated that these could potentially inhibit RAGEs activity and be used in the clinical management of various diseases.